CLOSE-3

Clinical Trial

2022-000624-37 Recruiting, Active

CLOSE-3

A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).

Phase 3

Interventional

Disease

Disease type

Paediatric clinical trials

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

05/10/2022

Inclusion criteria :

Exclusion criteria :

Funding

private

Members involved

Others investigators

Dr Marta Morales Ballús

Representative

Spain

Anterior Segment Rare Eye Diseases (WG4), CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8)

Dr Susana Noval

Representative

Spain

Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader